NASDAQ · CLNNHealthcarePharmaceuticals

Clene financials

$4.10+0.99%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY25
Dec 31
FY24
Dec 31
FY23
Dec 31
FY22
Dec 31
FY21
Dec 31
FY20
Dec 31
Revenue$200.0K$342.0K$654.0K$473.0K$723.0K$206.0K
Gross profit$157.0K$272.0K$533.0K$447.0K$434.0K$141.0K
Gross margin78.5%79.5%81.5%94.5%60.0%68.4%
Operating income-$23.1M-$33.1M-$40.5M-$48.4M-$50.0M-$20.2M
Net income-$26.2M-$39.4M-$49.5M-$29.9M-$9.7M-$19.3M
Net margin−13086.5%−11520.5%−7569.4%−6325.2%−1347.2%−9357.8%
Diluted EPS$-2.65$-5.67$-9.43$-9.20$-3.20$-22.00
EBITDA-$21.6M-$31.4M-$38.8M-$47.0M-$48.9M-$19.3M
Operating cash flow-$18.5M-$21.3M-$30.2M-$39.0M-$34.6M-$18.9M
Free cash flow-$18.6M-$21.3M-$30.5M-$44.2M-$36.0M-$19.3M
Diluted shares9.9M7.0M5.2M3.3M3.1M0.9M

Balance sheet

Period endDec 31Dec 31Dec 31Dec 31Dec 31Dec 31
Cash & equivalents$5.2M$12.2M$28.8M$18.3M$50.3M$59.3M
Short-term investments$0.00$0.00$6.2M$5.0M$0.00—
Total debt$17.6M$15.8M$26.7M$25.8M$19.3M$2.3M
Total assets$18.1M$27.3M$52.3M$44.5M$63.1M$68.2M
Total liabilities$35.7M$36.2M$39.0M$41.3M$50.5M$67.9M
Shareholders' equity-$17.6M-$8.9M$13.4M$3.2M$12.6M$341.0K

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology